Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Migenix hepatitis study samples require retesting
Schering-Plough was supplying Pegetron (peginterferon alfa-2b powder for solution plus ribavirin 200 mg capsules) as well as other services for the trial as part of an agreement between
Schering-Plough was supplying Pegetron (peginterferon alfa-2b powder for solution plus ribavirin 200 mg capsules) as well as other services for the trial as part of an agreement between
The EU and Japan have been working collaboratively for many years in the area of human medicines regulation. However, they will now be able to exchange confidential information
This is the second indication for which the European Medicines Agency (EMEA) has been granted orphan drug status to Fodosine following regulatory submissions by BioCryst's partner Mundipharma. The
The trial was conducted in China using the vaccination technology exclusively licensed to Opexa. The results demonstrated that T-cell vaccination was well tolerated and, importantly, induced T-cell regulatory
Under the terms of the agreement, KineMed will identify new therapeutic utility by applying its proprietary translational medicine technologies, AquaTag and KineMarker. Once a disease target is established
Under the original agreement, Ranbaxy conducted the optimization chemistry required to progress drug leads to the stage of candidate selection. Under the new agreement, Ranbaxy will advance leads
Orion is in negotiations about the extra study with the drug's license holder Abbott. Simdax is an is an Orion-originated compound which it licnesed to Abbott in 2004.
“Although new antiviral agents are in development, therapies are needed to reduce liver injury in patients with chronic hepatitis and to reduce inflammation and fibrosis,” said Dr Edward
Roche said it will be introducing a new operating model for its global research and development activities, organized around disease biology areas (DBA). Each DBA will cover activities
UCB now holds the global patent and marketing rights to the cancer antibody, CDP-791. As a result of this, ImClone now has the right to receive royalties on